NDAORALSYRUP
Approved
Jul 1954
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MULTIFUGE is a piperazine citrate oral syrup approved in 1954 for parasitic infections. The drug functions as an anthelmintic agent targeting intestinal worms. It represents a legacy oral treatment in an aging product portfolio.
LOE Approaching
Declining product with minimal linked job opportunities; marketing and field teams likely operating at reduced capacity.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MULTIFUGE offers minimal career growth potential given the approaching LOE, zero linked job openings, and declining market activity. This assignment typically indicates transition roles, consolidation functions, or career stability roles within a legacy portfolio rather than advancement opportunity.
Brand Manager (legacy)Field Sales
Worked on MULTIFUGE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.